A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
← catalyst calendarNCT06698796 · readout in 463 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
211estimated
Sites
24
Countries
Argentina, Bulgaria, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-22 | actual | When the study began enrolling |
| Primary completion | 2027-11-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dermatomyositis
- Polymyositis
Intervention
- Drug: Dazukibart
Primary outcomes
what the primary-completion date above is the date OFTreatment-Emergent Adverse Events (AEs), Serious AEs, AEs of Special Interest, and AEs leading to treatment discontinuation
measured 52 weeks
Number of participants with clinically significant laboratory abnormalities
measured 52 weeks
Number of participants with clinically significant abnormalities in vital signs
measured 52 weeks
Number of participants with clinically significant electrocardiogram (ECG) abnormalities
measured 52 weeks
Change from baseline in Forced Vital Capacity (FVC)/Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
measured 52 weeks
Absolute values and change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
measured 52 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed